Stock overview
Ascendis Pharma A/S - US
Explore the company, reported ownership, price history, and available source evidence.
Ascendis Pharma ordinary shares, traded on Nasdaq as ASND since April 20, 2026 following the one-for-one ADS exchange. Ascendis develops and commercializes medicines using its TransCon technology.
- Last close
- $270.33
- · ASND
- Tracked holders
- 3 funds
- Latest available 13F per fund
ASND · USD
Price
Close · Nov 18, 2026
- Range low
- $205.81
- Range high
- $277.18
- Observations
- 149
- Session date
- Nov 18, 2026
Apr 20, 2026–Nov 18, 2026. Regular market hours only. Historical prices are unadjusted; splits and other corporate actions can affect comparisons.
Investor Popularity
Rows are narrowed by movement, fund type, and position size.
| Fund | Move | Value | Weight |
|---|---|---|---|
| Renaissance Technologies largest tracked holder Q3 2026 · filed Nov 12, 2026 · SEC filing | −21% 26'Q3 | $21,689,188 | 0.03% |
| Gotham Asset Management position history Q3 2026 · filed Nov 16, 2026 · SEC filing | Newly reported 26'Q3 | $13,400,049 | 0.03% |
| Polen Capital Management position history Q3 2026 · filed Nov 13, 2026 · SEC filing | Newly reported 26'Q3 | $4,980,364 | 0.05% |
SEC Forms 4/5
Insiders
Financials
Official-source analysis
AI Earnings Report
No published AI Earnings Report yet
We publish a cited AI Earnings Report after an eligible official earnings filing is accepted and passes validation.
Options market